skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Brain Metastases From Breast Carcinoma: Validation of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification and Proposition of a New Prognostic Score

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [2];  [3]; ; ; ; ;  [1];  [4]; ; ;  [1]
  1. Department of Radiation Oncology, Centre Rene Huguenin, Saint Cloud (France)
  2. Department of Medical Statistics, Centre Rene Huguenin, Saint Cloud (France)
  3. Department of Pathology, Centre Rene Huguenin, Saint Cloud (France)
  4. Department of Medical Oncology, Centre Rene Huguenin, Saint Cloud (France)

Purpose: To validate the Radiation Therapy Oncology Group Recursive Partitioning Analysis (RTOG RPA) classification and determine independent prognostic factors, to create a simple and specific prognostic score for patients with brain metastases (BM) from breast carcinoma treated with whole-brain radiotherapy (WBRT). Methods and Materials: From January 1998 through December 2003, 132 patients with BM from breast carcinoma were treated with WBRT. We analyzed several potential predictors of survival after WBRT: age, Karnofsky performance status, RTOG-RPA class, number of BM, presence and site of other systemic metastases, interval between primary tumor and BM, tumor hormone receptor (HR) status, lymphocyte count, and HER-2 overexpression. Results: A total of 117 patients received exclusive WBRT and were analyzed. Median survival with BM was 5 months. One-year and 2-year survival rates were 27.6% (95% confidence interval [CI] 19.9-36.8%) and 12% (95% CI 6.5-21.2%), respectively. In multivariate analysis, RTOG RPA Class III, lymphopenia ({<=}0.7 x 10{sup 9}/L) and HR negative status were independent prognostic factors for poor survival. We constructed a three-factor prognostic scoring system that predicts 6-month and 1-year rates of overall survival in the range of 76.1-29.5% (p = 0.00033) and 60.9-15.9% (p = 0.0011), respectively, with median survival of 15 months, 5 months, or 3 months for patients with none, one, or more than one adverse prognostic factor(s), respectively. Conclusions: This study confirms the prognostic value of the RTOG RPA classification, lymphopenia, and tumor HR status, which can be used to form a prognostic score for patients with BM from breast carcinoma.

OSTI ID:
21039590
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 69, Issue 3; Other Information: DOI: 10.1016/j.ijrobp.2007.04.024; PII: S0360-3016(07)00695-5; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Institutional, Retrospective Analysis of 777 Patients With Brain Metastases: Treatment Outcomes and Diagnosis-Specific Prognostic Factors
Journal Article · Mon Jul 15 00:00:00 EDT 2013 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21039590

Predictors of Survival in Contemporary Practice After Initial Radiosurgery for Brain Metastases
Journal Article · Fri Mar 01 00:00:00 EST 2013 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21039590

Prognostic Factors for Survival in Patients Treated With Stereotactic Radiosurgery for Recurrent Brain Metastases After Prior Whole Brain Radiotherapy
Journal Article · Tue May 01 00:00:00 EDT 2012 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21039590